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Abstract: The prevalence of allergic diseases such as allergic rhinitis
(AR) and asthma are markedly increasing to epidemic proportions
worldwide as societies adopt Western lifestyles. An estimated 300
million persons worldwide have asthma, about 50% of whom live in
developing countries, and about 400 million people suffer from AR.
AR has a marked impact on quality of life, socially, at school, and in
the workplace and is a huge socioeconomic burden. Thus, there was
clearly a need for a global evidence-based guideline not only for
managing AR but also highlighting the interactions between the
upper and lower airways including diagnosis, epidemiology, com-
mon risk factors, management, and prevention. The Allergic Rhinitis
and its Impact on Asthma (ARIA) document was ﬁrst published in
2001 as a state-of-the-art document for the specialist, the general
practitioner, and other health care professionals. Subsequent research
and increasing knowledge have resulted in the ARIA 2008 update.
The present review summarizes the ARIA update with particular
emphasis on the current status of AR and asthma in Asia Paciﬁc.
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Allergic rhinitis (AR) is an IgE-mediated inﬂammation ofthe nasal mucosa induced after allergen exposure and
presents with the 3 cardinal symptoms of sneezing, nasal
obstruction, and rhinorrhea. AR is a global health problem
that causes major illness and disability worldwide. It affects
social life, sleep, school, and work.1–5 The economic impact
of AR is substantial.
More than 400 million patients suffer from AR6–9 but
there are still differences between rural and urban areas,
both in developed and developing countries,8,10–12 possibly
because of differences in immune reactions.13 A large number
of patients also suffer from nonallergic rhinitis14 but the
characterization of this disease is unclear as there are many
phenotypes of nonallergic rhinitis.
In 2001, the ARIA (Allergic Rhinitis and its Impact on
Asthma) World Health Organization (WHO) evidence-based
document was published15 and the statements of evidence for
the development of ARIA followed WHO rules and were
based on those of Shekelle et al.16
The ARIA document was intended to be a state-of-the-
art review for the specialist and for the general practitioner
and other health care professionals to update their knowledge
of AR, to highlight the impact of AR on asthma, to provide
an evidence-based documented revision on the diagnosis
methods and the treatments available, and to propose a step
wise approach to the management of the disease.
ARIA UPDATE 2008
As a result of a large number of papers with new
information on existing drugs, mechanisms, and newer
therapies published during the past 7 years,17–22 it was
important to have an ARIA update.
• The ARIA classiﬁcation proposed “intermittent and per-
sistent” have been validated,23–26 although some authors
proposed extension of the severity of AR to 3 levels.27,28
However, because this would not lead to treatment
differences, the ARIA experts proposed continuation
of the classiﬁcation of rhinitis severity as “mild” or
“moderate/severe.”
• New methods of diagnosis have been proposed for aller-
gic and nonallergic rhinitis.29–32 The diagnosis of AR is
often easy, but in some cases it may cause problems and
many patients are still underdiagnosed, often because they
do not perceive the symptoms of rhinitis as a disease.
• Furthermore, the gaps in our knowledge in the ﬁrst
ARIA document, which include some aspects of treat-
ment with complementary and alternative medicine,18
sports and rhinitis in athletes,19,33,34 and rhinitis and its
links with asthma in children,35–41 have been addressed
in the ARIA update.
A large list of treatments was considered in the ARIA
2008 update.42–44 With respect to pharmacologic treatments,
intranasal corticosteroids have been recommended to be the
ﬁrst-line therapy in patients with moderate to severe disease
and are also effective on ocular symptoms,45 H1 antihistamines
are important treatments for all patients, and leukotriene
receptor antagonists are particularly important for patients with
rhinitis and asthma.46,47 However, tertiary prevention of allergy
is still a matter of debate because clinical trials do not usually
show any efﬁcacy of single allergen avoidance measures.17
Sublingual allergen-speciﬁc immunotherapy has proven to be
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a safe and effective treatment,48–51 but clinical trials need to be
standardized.52,53 An algorithm of the management of AR is
provided (Fig. 1). However, there is continuous progress in our
understanding of the mechanisms of AR, and novel treatment
approaches are constantly published.54 Nonallergic rhinitis is
still a matter of discussion and effective treatment may be
difﬁcult.55
Another important aspect of the ARIA update was to
consider the comorbidities of AR, and in particular asthma.
Epidemiologic studies have consistently shown that asthma
and rhinitis often coexist in the same patients in every region
of the world.56–59 Most patients with asthma have rhinitis,
but the prevalence of asthma in patients with rhinitis still
needs to be assessed.60,61 Adults and children with asthma
and documented concomitant AR experience more asthma-
related hospitalizations and physician visits, and incur higher
asthma drug costs, than adults with asthma alone.62–65 These
patients also experience more frequent absences from work
and decreased productivity. However, some studies have not
shown such an association.66
Many patients with AR have an increased bronchial
reactivity to methacholine or histamine,67 especially during
and some time after the pollen season.68,69 Nasal and bron-
chial inﬂammation are often related,70 but remodeling of the
nose and bronchi seem to differ.71
Intranasal treatment of the nose does not considerably
impact the lower airways,72 possibly because the characteriza-
tion of seasonal asthma needs more insight73 and most studies
have been carried out on this disease. However, some compel-
ling data suggest that new studies with innovative methods
need to be initiated.47,74,75 Oral drugs acting on asthma and
rhinitis have an effect on both sites.46 Research has also shown
that the addition of nasal topical corticosteroids to standard
asthma treatment reduces severe exacerbations of asthma by
FIGURE 1. An algorithm of the management of Allergic Rhinitis ARIA update 2008.
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almost 50%.79 Allergen-speciﬁc immuno-therapy in patients
with AR has a prolonged preventive effect on the development
of asthma when stopped.76
ASTHMA AND ALLERGIC RHINITIS IN
ASIA PACIFIC
The prevalence of allergic diseases in Asia varied widely
but was found to be rising (asthma 29.1%; AR up to 45%)
mostly in low- and middle-income countries.80,81 In Thailand,
the prevalence of all 3 major allergic diseases increased sig-
niﬁcantly from the ISAAC phase I survey performed in 1995;
that is, asthma increased from 12.2% to 14.5%, AR from
37.9% to 50.6%, and eczema from 9.8% to 15.7%. In Japan,
rhinitis has increased from 3.8% in 1982 to 32% and asthma
from 4.6% in 199282 to 9.1% (Akasawa A, 2006, unpublished)
and more than 42% of patients with asthma have AR. The
prevalence of childhood asthma in Taiwan has increased
from 1.3% in 1974 to 5.07% in 1985,83 and more recently,
the overall cumulative and 12-month prevalence of wheezing
and rhinitis in younger children 10 to 12 years was 8.2% and
44.4%, respectively; and in the older children 13 to 15 years,
6.9% and 42.2%.84 Similarly, in Singaporean preschoolers, the
cumulative and previous 12-months prevalence of wheezing
was 27.5% and 16.0%, respectively, and the current asthma and
rhinitis prevalence was 11.7% and 25.3%, respectively. By con-
trast, the prevalence of current wheezing, diagnosed asthma,
and allergic rhinoconjunctivitis in Tibet was 0.8%, 1.1%, and
5.2%, respectively.85 Although asthma prevalence in rural
Bangladesh is 16.1%86 and in Pakistan there is a doubling
of the prevalence of AR and asthma in ISAAC III as com-
pared with ISAAC I, in a study in urban India the overall
prevalence of asthma was 2.38%.87 Prevalence of allergic
rhinitis in 5- to 11-year-old children in Vietnam is
34.9%88 and prevalence of allergic rhinitis in patients with
asthma is 48.54% (Le Van Khang et al. Study of sensitivity,
speciﬁcity of house dust mite allergen made in Vietnam in
diagnosis of asthma. Ministry of Health of Vietnam, January
2002 to December 2004, www.cimsi.org.vn). Asthma prev-
alence in Australia increased from 8% in 1989–1990 to 11%
in 1995 but the prevalence plateaued in recent years with
a 2004 prevalence of asthma at 14% to 16% of children and
10% to 12% of adults.89
Although overall regional data for adults is scant, it is
estimated that 1% to 10% have asthma and 10% to 32% have
AR. In a more recent study, the self-reported prevalence of
AR in China had wide variations, ranging from ,10% to
.20%, with about 15% suffering from persistent AR.90 More
recent data showed an increase in prevalence of AR in Korea
from 6% to 10%90 to .20%91 in the adult population. The
distribution of the severity of AR was mild intermittent
(25.7%), moderate to severe intermittent (16.4%), mild per-
sistent (16.4%), and moderate to severe persistent (41.2%).92
Comorbid Allergic Rhinitis and Asthma
Recent data showed a very high comorbid rate of
asthma and rhinitis as 60% to 80% of patients with asthma
had rhinitis symptoms.93 The younger patients with asthma
had a higher comorbid rate of rhinitis (80%) than elderly
patients (60%); furthermore, patients with asthma who also
had rhinitis presented more severe clinical symptoms in both
adults and children, indicating that rhinitis may affect asthma
severity and outcome.93
Although aeroallergens that trigger allergy and asthma
in Asia Paciﬁc vary from area to area, house dust mites are
the major triggering allergen in most of Asia followed by
pollens, insects, molds, and fungi.94
Impact on Quality of Life
In a study on patient perceptions of asthma manage-
ment across Asia, patients reported frequent and unnecessary
symptoms and exacerbations because of a lack of adequate
asthma control.95 Twenty-seven percent of adults and 37%
of children with asthma reported absences from work or
school in the previous year because of asthma, and 40%
required hospitalization, emergency department visits, or
unscheduled emergency visits to other health care facilities
in the previous year.95 Asthma severity varied, with Vietnam
and China reporting the most patients with severe, persistent
symptoms. Absenteeism from work was highest in the
Philippines (46.6%) and lowest in South Korea (7.5%). In
a survey of parents of children with asthma in 4 Asian coun-
tries, most children with asthma (73%) had pre-existing
symptoms of AR and asthma with comorbid AR substantially
affecting their quality of life and worsening their asthma
symptoms.5 However, awareness of the comorbidity of AR
and asthma among the parents of children with asthma was
only about 50%.
From the evidence listed in this summary, it is clear that
there is a high linkage between asthma and AR in the Asia
Paciﬁc too. It is therefore recommended that patients with
persistent AR should be evaluated for asthma, including
appropriate history taking and spirometric parameters, at an
early stage. However, patients with asthma should be
evaluated for rhinitis. Unfortunately, in reality there is a gap
in this practice in many countries in the region. Partly, this is
due to the lack of allergy medicine as a recognized speciality
in some countries and to governmental regulations restricting
specialists to practice as organ-based specialists. To resolve
this problem and to have an integrated therapeutic strategy is
one of the major challenges in the Asia-Paciﬁc region.
On the basis of these constraints, we also need to
consider treatment strategies that can really treat both the
upper and the lower airway diseases. Leukotriene receptor
antagonists are recommended for patients with both rhinitis
and asthma in this ARIA summary. As the only established
etiological treatment for allergic diseases, allergen-speciﬁc
immunotherapy (SIT) needs to be highlighted as well.
CONCLUSIONS
The prevalence of asthma and AR is increasing in Asia
Paciﬁc and the prevalence of comorbidity is high.96 The per-
ception of patients and physicians regarding the links between
asthma and rhinitis varies between countries, but seems to be
higher than expected.77,78 However, knowledge is not directly
translated into practice because fewer physicians coprescribe
treatments for rhinitis and asthma in the same patient.
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The recommendations of the ARIA workshop in 1999
are still valid,15 and in particular, it is recommended that
all patients with AR, particularly if it is persistent, should
be evaluated for asthma. AR is not only a risk factor for
underlying asthma but could be a risk factor for asthma exac-
erbations. Patients with asthma should likewise be evaluated
for rhinitis, and a combined strategy should ideally be used to
treat the upper and lower airway diseases in terms of efﬁcacy
and safety.
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